Cinchophen

Summary

Cinchophen (CHEMBL348000) is an approved small molecule (ATC M04AC02); indicated across 1 condition including gout.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M04AC02
• Indications: 1 condition
• Chemistry: 249.26 Da · C16H11NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL348000
Name	Cinchophen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8593
ATC	M04AC02
Molecular formula	C16H11NO2
Molecular weight	249.26
InChIKey	YTRMTPPVNRALON-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)O

IUPAC name: 2-phenylquinoline-4-carboxylic acid

Also known as: Cinchophen, Cinchophene, Cincofeno, NSC-2617, SID4262559, SID855522, SID104171373, SID26751442, SID50085459, cinchophen, SID124883501, SID124883499

Patent coverage: 933 distinct patent families (3,180 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,161 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, cAMP and cAMP-inhibited cGMP 3’,5’-cyclic phosphodiesterase 10A.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	6.35	Potency	446.7	nM	CHEMBL_ACT_3889416
LMNA	5.1	Potency	7943	nM	CHEMBL_ACT_3646209

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
gout	4	MONDO:0005393	EFO:0004274

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).